Home

Peter L. Hoang

CIK 1626893 · President and CEO · last filed 2022-03-28

Peter L. Hoang is a President and CEO who has filed 11 SEC Form 4 insider transactions across 3 companies since 2015. The most recent filing, for MRKR, was dated Mar 28, 2022. Across all open-market trades the lifetime net is +$296.2K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $61.1K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$61.1K

Companies

3

Total Filings

11

Lifetime Open-Market Net

$296.2K

Filer Profile

Reported Address
C/O BELLICUM PHARMACEUTICALS, INC.
2130 W. HOLCOMBE BLVD., STE. 800
HOUSTON, TX 77030
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MRKR President and CEO 53,166 $1.15 $61.1K $296.2K 7 2022-03-28
Marker Therapeutics, Inc. (TPIV) Delisted CEO and President 179,711 — — $0 1 2017-09-25
BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted Sr. VP of Bus. Development — $0.07 — $0 3 2017-01-05

Recent Filings

11 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-03-28 MRKR Mixed +150,718 -$23.5K EDGAR
2022-02-22 MRKR Grant (A) — $0 EDGAR
2021-03-18 MRKR Buy (P) +142,857 $250.0K EDGAR
2021-02-12 MRKR Grant (A) — $0 EDGAR
2020-03-12 MRKR Grant (A) — $0 EDGAR
2019-08-15 MRKR Buy (P) +10,000 $46.2K EDGAR
2018-10-23 MRKR Grant (A) — $0 EDGAR
2017-09-25 Marker Therapeutics, Inc. (TPIV) Delisted Mixed +179,711 $571.5K EDGAR
2017-01-05 BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted Grant (A) — $0 EDGAR
2016-01-06 BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 11
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.